How does this company make money?
The company earns revenue each time CABOMETYX tablets or COMETRIQ capsules are shipped to specialty distributors and hospital systems. Revenue is recorded at the point of shipment. The final amount collected depends on negotiations with insurance payers and on discounts applied through patient assistance programs that help cover costs for eligible patients.
What makes this company hard to replace?
Before an oncologist can prescribe CABOMETYX, they must document that the patient already failed anti-angiogenic therapy and then obtain prior authorization from the patient's insurance plan — a process built specifically around this drug. Patients who are already taking cabozantinib and managing its side effects are reluctant to switch to a different kinase inhibitor that comes with a different and unfamiliar set of side effects. Specialty pharmacy networks that have already set up distribution, prior authorization workflows, and patient support services for CABOMETYX face their own costs and friction in switching to an alternative.
What limits this company?
The only way to grow into new cancers is to run a separate Phase III clinical trial for each one, and those trials take three to five years. The drug itself can be manufactured efficiently once the ingredient supply is in place, but finding and enrolling enough patients with the right cancer type at qualified trial sites is slow and cannot be sped up by spending more money. Each new indication is its own years-long project.
What does this company depend on?
The company cannot operate without FDA approval for CABOMETYX in renal cell carcinoma and FDA approval for COMETRIQ in medullary thyroid cancer — lose either and that product cannot be sold. It also depends on contract manufacturers to supply the cabozantinib active pharmaceutical ingredient, on oncology clinical trial sites capable of enrolling advanced cancer patients to expand into new indications, and on its partnership with Genentech for COTELLIC commercialization rights.
Who depends on this company?
Oncologists treating advanced renal cell carcinoma would lose a key second-line treatment option for patients who have already tried anti-angiogenic therapy. Endocrinologists managing progressive medullary thyroid cancer would lose the main targeted drug available for patients whose disease has spread. Specialty oncology pharmacies that dispense CABOMETYX and COMETRIQ — and run the prior authorization and patient assistance programs around them — would lose a significant oral cancer medication from their operations.
How does this company scale?
Once the cabozantinib drug supply is secured, making more tablets and capsules through contract manufacturing is relatively straightforward and does not hit hard limits quickly. What does not scale easily is expansion into new cancer types — every new indication requires its own Phase III trial, its own patient population, its own regulatory submission, and its own commercial launch, none of which can be shared or recycled from a prior approval.
What external forces can significantly affect this company?
Medicare Part D coverage decisions directly affect whether patients can afford CABOMETYX, since it is a high-cost oral cancer drug. The European Medicines Agency has its own trial design requirements that may not line up with what the FDA needed, forcing parallel development work. And policies governing how long a drug's patent exclusivity lasts before generics are allowed in determine exactly how much time cabozantinib has before cheaper copies can enter the market.
Where is this company structurally vulnerable?
If the patent on cabozantinib expires or a generic manufacturer successfully challenges it in court before a replacement drug reaches approval, other companies can legally copy the molecule. That would collapse sales of both CABOMETYX and COMETRIQ at the same time, because both products are the same underlying chemical — and there is no approved backup drug ready to replace that revenue.
CompanyGraph